ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 6 for:    MN-166

A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02714036
Recruitment Status : Recruiting
First Posted : March 21, 2016
Last Update Posted : April 11, 2018
Sponsor:
Collaborators:
Massachusetts General Hospital
South Shore Neurologic Associates
Information provided by (Responsible Party):
MediciNova

Brief Summary:

This is a multi-center, open-label study of MN-166 (ibudilast) in subjects with ALS. To be eligible subjects must meet the El Escorial criteria of possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS. Safety, tolerability, blood, neuro-imaging biomarkers, and clinical outcomes will be collected on all subjects. Subjects will receive study drug for 36 weeks.

The study will consist of a Screening Phase (up to 6 weeks), an Open-Label Treatment Phase (36 weeks) and a Off-Treatment Follow-up Phase (4 Weeks).

Number of Subjects (Planned):

Approximately 45 subjects are planned to be screened with the goal of enrolling 35 subjects.


Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Drug: ibudilast Phase 1 Phase 2

Detailed Description:

This is a multi-center, open-label study of MN-166 (ibudilast) in subjects with ALS. To be eligible subjects must meet the El Escorial criteria of possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS. Safety, tolerability, blood, neuro-imaging biomarkers, and clinical outcomes will be collected on all subjects. Subjects will receive study drug for 36 weeks.

The study will consist of a Screening Phase (up to 6 weeks), an Open-Label Treatment Phase (36 weeks) and a Off-Treatment Follow-up Phase (4 Weeks).

During the Screening Phase, eligible ALS subjects will sign an informed consent form and the following screening assessments will be performed: review of inclusion/exclusion criteria: El Escorial ALS Diagnostic criteria, medical history and demographics, ALS diagnosis history, physical and neurological examination, U. Penn upper motor Neuron Burden (UMNB), pulmonary function tests, vital signs including height and weight, blood for safety labs including TSPO affinity test, ECG and review and documentation of concomitant medications and therapies.

Screening Phase (up to 6 weeks) The Treatment Phase will consist of a Baseline visit and 3 subsequent clinic visits at Weeks 4, 12, 24, and 36. Telephone follow-ups will occur at Weeks 1, 2, 8, 16, 20, 28, and 32.

Open-Label Treatment Phase (36 weeks) At the Baseline visit, subjects will return to the clinic and the following assessments will be performed/administered: review of inclusion and exclusion criteria for continued eligibility, vital signs, blood for safety labs and biomarkers, ECG, ALSFRS-R questionnaire, slow vital capacity (SVC), baseline strength as measured by hand held dynamometry (HHD), and Columbia Suicide Severity Rating Scale (C-SSRS). At this visit, study drug will be dispensed, and adverse events, concomitant medications and therapies will be assessed and documented. At subsequent visits during the Treatment Phase, similar assessments will be performed.

In addition, a [11C]PBR28-PET scan will be performed once between the Screening and Baseline visit, and once between the Week 20 and Week 28 phone calls. The ALSFRS-R, SVC and U Penn Upper Motor Neuron Burden will be repeated on the same day as the PET scans.

The follow-up visit will consist of a telephone call to document adverse events and concomitant therapies


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)
Study Start Date : March 2016
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : December 2018


Arm Intervention/treatment
Experimental: MN-166 (ibudilast)
MN-166 (ibudilast) 10 mg capsules administered orally. Fifty (50) mg b.i.d. (5 capsules) in the morning and 50 mg b.i.d. (5 capsules) evening will be administered for a total daily dose of 100 mg/d. Study drug dosing may vary based on individual tolerability.
Drug: ibudilast
Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration16. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
Other Names:
  • MN-166
  • AV411



Primary Outcome Measures :
  1. To measure the impact of MN-166 (ibudilast) on [11C]-PBR28 uptake in the motor cortices and brain stem measured by positron emission tomography (PET) imaging at 24 weeks [ Time Frame: 24 weeks ]
    This is measured as the ratio of standardized uptake value (SUVR).

  2. To measure the impact of MN-166 (ibudilast) on several markers of neuro-inflammation measured by blood biomarkers [ Time Frame: 36 weeks ]
    Blood biomarkers for neuroinflammation include tumor necrosis factor(TNF)-alpha, interferon (IFN)-gamma, interleukin (IL)-1, IL-6, and IL-10. All blood biomarkers are measured in picrograms/milliliter (pg/mL).


Secondary Outcome Measures :
  1. To evaluate the safety and tolerability of MN-166 by assessing the number of treatment-related adverse events. [ Time Frame: 36 weeks ]
  2. To evaluate the effect of ibudilast on ALS functional rating scale-revised (ALSFRS-R) [ Time Frame: 36 weeks ]
    ALSFRS-R is a clinical assessment for function. It measures speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency. The scale ranges from 0 (no ability) to 4 (normal ability). The Total Score of these sub-assessments is the ALSFRS-R score.

  3. To evaluate the effect of ibudilast on slow vital capacity (SVC) [ Time Frame: 36 weeks ]
    SVC is measured as SVC predicted liters.

  4. To evaluate the effect of ibudilast on strength as measured by Hand-held dynamometry (HHD) [ Time Frame: 36 weeks ]
    HHD assesses strength and is measured in kilograms (kg).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must be diagnosed as having possible, probable, probable-laboratory supported, or definite ALS, either sporadic or familial according to modified El Escorial criteria.
  2. Age 18 or above, able to provide informed consent, and safely comply with study procedures.
  3. Vital capacity (VC) of at least 50% predicted value for gender, height and age at screening visit, or in the opinion of the study physician, able to safely tolerate study procedures. (Not applicable to flexible arm)
  4. Subject must be able to swallow oral medication at the Baseline Visit and expected to be able to swallow the capsules throughout the course of the study.
  5. Subject must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to screening (riluzole-naïve participants are permitted in the study). (Not applicable to flexible arm)
  6. Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control) for the duration of the study and 3 months after study completion.
  7. Males should practice contraception for the duration of the study and 3 months after completion.
  8. Ability to safely lie flat for 90 min for PET procedures in the opinion of the study physician. (Not applicable to flexible arm)
  9. High or mixed affinity to bind TSPO protein (Ala/Ala or Ala/Thr) (see section 7.2.1). (Not applicable to flexible arm)
  10. Upper motor Neuron Burden (UMNB) Score ≥25 (out of 45) at screening visit. (Not applicable to flexible arm)

Exclusion Criteria:

  1. Abnormal liver function defined as AST and/or ALT > 3 times the upper limit of the normal.
  2. Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal.
  3. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the participant to provide informed consent, according to PI judgment.
  4. Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the study.
  5. History of HIV, clinically significant chronic hepatitis, or other active infection.
  6. Active inflammatory condition of autoimmune disorder (Not applicable to flexible arm)
  7. Females must not be lactating or pregnant.
  8. Active participation in another ALS clinical trial or exposure to an off label ALS experimental treatment within 30 days of the Baseline Visit (Not applicable to flexible arm)
  9. Exposure to immunomodulatory medications within 30 days of the Baseline Visit. (Not applicable to flexible arm)
  10. Any contraindication to undergo MRI studies such as

    • History of a cardiac pacemaker or pacemaker wires
    • Metallic particles in the body
    • Vascular clips in the head
    • Prosthetic heart valves
    • Claustrophobia (Not applicable to flexible arm)
  11. Radiation exposure that exceeds the site's current guidelines (Not applicable to flexible arm)
  12. EKG finding of QTc prolongation > 450 ms for males and > 470 ms for females at screening or baseline.
  13. Not on any prohibitive medication or known QT prolonging medication:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02714036


Contacts
Contact: Catherine Cebulla, CRC 617-643-6252 ccebulla@partners.org
Contact: Melissa K Arnold, RN, BSN 617-643-5581 MKarnold@partners.org

Locations
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Catherine Cebulla, CRC    617-643-6252    ccebulla@partners.org   
Contact: Danica L. Sanders, RN    617-643-6249    dlsanders@mgh.harvard.edu   
Principal Investigator: Nazem Atassi, MD, MMSc         
Sub-Investigator: Sabrina Paganoni, MD, PhD         
Sub-Investigator: James D Berry, MD, MPH         
Sub-Investigator: Katherine Nicholson, MD         
Sub-Investigator: Melissa Arnold, RN, BSN         
Sub-Investigator: Suma Babu, MD         
United States, New York
South Shore Neurologic Associates, P.C. Recruiting
Patchogue, New York, United States, 11772
Contact: Lori J Fafard, RN    631-758-1910 ext 2205    lfafard@southshoreneurologic.com   
Contact: Kristen Capriola, RN    631-758-1910 ext 2206    kcapriola@southshoreneurologic.com   
Principal Investigator: Mark Gudesblatt, MD         
Sub-Investigator: Myassar Zarif, MD         
Sub-Investigator: Barbara Bumstead, NP         
Sub-Investigator: Lori Fafard, RN         
Sub-Investigator: Laura Graffitti, RN         
Sub-Investigator: Kristen Capriola, RN         
Sub-Investigator: Stephanie Galarza, SC         
Sub-Investigator: Erin Vacey, SA         
Sponsors and Collaborators
MediciNova
Massachusetts General Hospital
South Shore Neurologic Associates
Investigators
Principal Investigator: Nazem Atassi, MD, MMSc Massachusetts General Hospital

Publications:

Responsible Party: MediciNova
ClinicalTrials.gov Identifier: NCT02714036     History of Changes
Other Study ID Numbers: MN-166-ALS-1202
First Posted: March 21, 2016    Key Record Dates
Last Update Posted: April 11, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by MediciNova:
ALS

Additional relevant MeSH terms:
Sclerosis
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Ibudilast
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Vasodilator Agents